202 related articles for article (PubMed ID: 31555258)
1. Regulatory T Cells Control the Switch From
Martinez LM; Robila V; Clark NM; Du W; Idowu MO; Rutkowski MR; Bos PD
Front Immunol; 2019; 10():1942. PubMed ID: 31555258
[TBL] [Abstract][Full Text] [Related]
2. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
3. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.
Bos PD; Plitas G; Rudra D; Lee SY; Rudensky AY
J Exp Med; 2013 Oct; 210(11):2435-66. PubMed ID: 24127486
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
5. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
[TBL] [Abstract][Full Text] [Related]
9. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.
Hix LM; Karavitis J; Khan MW; Shi YH; Khazaie K; Zhang M
J Biol Chem; 2013 Apr; 288(17):11676-88. PubMed ID: 23486482
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.
Gupta S; Joshi K; Wig JD; Arora SK
Acta Oncol; 2007; 46(6):792-7. PubMed ID: 17653902
[TBL] [Abstract][Full Text] [Related]
11. The transcriptional repressor Bcl6 controls the stability of regulatory T cells by intrinsic and extrinsic pathways.
Sawant DV; Wu H; Yao W; Sehra S; Kaplan MH; Dent AL
Immunology; 2015 May; 145(1):11-23. PubMed ID: 25262912
[TBL] [Abstract][Full Text] [Related]
12. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
Abba MC; Gong T; Lu Y; Lee J; Zhong Y; Lacunza E; Butti M; Takata Y; Gaddis S; Shen J; Estecio MR; Sahin AA; Aldaz CM
Cancer Res; 2015 Sep; 75(18):3980-90. PubMed ID: 26249178
[TBL] [Abstract][Full Text] [Related]
13. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.
Steenbrugge J; Vander Elst N; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Dirix L; Van Laere S; Meyer E
Front Immunol; 2019; 10():2928. PubMed ID: 31921184
[TBL] [Abstract][Full Text] [Related]
14. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
15. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression.
Martinson HA; Jindal S; Durand-Rougely C; Borges VF; Schedin P
Int J Cancer; 2015 Apr; 136(8):1803-13. PubMed ID: 25187059
[TBL] [Abstract][Full Text] [Related]
16. A role for T-lymphocytes in human breast cancer and in canine mammary tumors.
Carvalho MI; Pires I; Prada J; Queiroga FL
Biomed Res Int; 2014; 2014():130894. PubMed ID: 24672781
[TBL] [Abstract][Full Text] [Related]
17. Modeling Human Ductal Carcinoma In Situ in the Mouse.
Behbod F; Gomes AM; Machado HL
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):269-278. PubMed ID: 30145750
[TBL] [Abstract][Full Text] [Related]
18. Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer.
Lawson JS; Tran DD; Carpenter E; Ford CE; Rawlinson WD; Whitaker NJ; Delprado W
J Clin Pathol; 2006 Dec; 59(12):1287-92. PubMed ID: 16698952
[TBL] [Abstract][Full Text] [Related]
19. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
20. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
Zuo Y; Ulu A; Chang JT; Frost JA
Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
